Turabi Khadija Shahab, Deshmukh Ankita, Paul Sayan, Swami Dayanand, Siddiqui Shafina, Kumar Urwashi, Naikar Shreelekha, Devarajan Shine, Basu Soumya, Paul Manash K, Aich Jyotirmoi
School of Biotechnology and Bioinformatics, DY Patil Deemed to Be University, CBD Belapur, Navi Mumbai, Maharashtra, 400614, India.
Centre for Cardiovascular Biology and Disease, Institute for Stem Cell Science and Regenerative Medicine (inStem), Bangalore, 560065, India.
Naunyn Schmiedebergs Arch Pharmacol. 2022 Oct;395(10):1139-1158. doi: 10.1007/s00210-022-02263-x. Epub 2022 Jun 13.
Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug's original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.
癌症是一种复杂的疾病,影响着全球数百万人。尽管手术和放射治疗取得了进展,但化疗仍然是治疗癌症的重要治疗选择。目前的治疗方法昂贵且有多种副作用。此外,随着时间的推移,癌细胞会对化疗产生耐药性,因此需要新的药物。药物重新利用是一种新颖的方法,专注于为旧的临床批准药物寻找新的应用。高维多组学领域的当前进展,尤其是蛋白质组学、基因组学和计算组学数据分析,促进了药物重新利用。药物重新利用方法提供了更便宜、有效且安全、副作用更少的药物,并加快了药物开发过程。该综述进一步阐述了每种重新利用药物在癌症中的原始适应症和作用机制。与此同时,本文还介绍了人工智能及其在药物重新利用中的应用。临床试验对于确定药物的安全性和有效性至关重要,因此本文报道了每种用于癌症的重新利用药物的临床研究,包括其阶段、状态和国家临床试验(NCT)标识。各种新出现的证据表明,重新利用药物对于更快、更经济地发现抗癌药物至关重要,基于人工智能的计算工具的出现可以加速转化癌症靶向管道。